(Q36385148)

13 August 2017

1 reference

title

The effects of statins on high-density lipoproteins (English)

1 reference

13 August 2017

1 reference

1

Ernst J Schaefer

1 reference

13 August 2017

Bela F Asztalos

2

1 reference

13 August 2017

publication date

1 January 2006

1 reference

Current Atherosclerosis Reports

13 August 2017

published in

1 reference

13 August 2017

volume

8

1 reference

13 August 2017

issue

1

1 reference

13 August 2017

page(s)

41-49

1 reference

https://scigraph.springernature.com/pub.10.1007/s11883-006-0063-3

13 August 2017

exact match

0 references

cites work

Clinical effects of rosuvastatin, a new HMG-CoA reductase inhibitor, in Japanese patients with primary hypercholesterolemia: an early phase II study

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11883-006-0063-3

Randomized dose-response study of rosuvastatin in Japanese patients with hypercholesterolemia

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11883-006-0063-3

Clinical efficacy and safety of rosuvastatin in Japanese patients with heterozygous familial hypercholesterolemia

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11883-006-0063-3

Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial

21 January 2018

1 reference

12 December 2020

Effects of atorvastatin on the HDL subpopulation profile of coronary heart disease patients

1 reference

12 December 2020

Cholesterol-lowering effects of rosuvastatin compared with atorvastatin in patients with type 2 diabetes -- CORALL study.

1 reference

12 December 2020

Comparative effects of rosuvastatin and gemfibrozil on glucose, insulin, and lipid metabolism in insulin-resistant, nondiabetic patients with combined dyslipidemia

1 reference

12 December 2020

Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial

1 reference

12 December 2020

Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial

1 reference

12 December 2020

Rosuvastatin and fenofibrate alone and in combination in type 2 diabetes patients with combined hyperlipidaemia

1 reference

12 December 2020

Comparative evaluation of the efficacy, safety, and tolerability of rosuvastatin 10 mg with atorvastatin 10 mg in adult patients with hypercholesterolaemia: the first Indian study.

1 reference

12 December 2020

Dyslipidemia management in adults with diabetes

1 reference

12 December 2020

Action of atorvastatin in combined hyperlipidemia : preferential reduction of cholesteryl ester transfer from HDL to VLDL1 particles

1 reference

12 December 2020

Comparative effects of rosuvastatin and atorvastatin across their dose ranges in patients with hypercholesterolemia and without active arterial disease

1 reference

12 December 2020

Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis

1 reference

12 December 2020

Intensive lipid lowering with atorvastatin in patients with stable coronary disease

1 reference

12 December 2020

Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre ra

1 reference

12 December 2020

Effects of atorvastatin on fasting and postprandial lipoprotein subclasses in coronary heart disease patients versus control subjects

1 reference

12 December 2020

Pharmacodynamic interaction between ezetimibe and rosuvastatin

1 reference

12 December 2020

Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S.

1 reference

12 December 2020

Value of high-density lipoprotein (HDL) subpopulations in predicting recurrent cardiovascular events in the Veterans Affairs HDL Intervention Trial

1 reference

12 December 2020

Rosuvastatin alone or with extended-release niacin: a new therapeutic option for patients with combined hyperlipidemia

1 reference

12 December 2020

High-density lipoprotein subpopulation profile and coronary heart disease prevalence in male participants of the Framingham Offspring Study

1 reference

12 December 2020

Effect on high-density lipoprotein cholesterol of maximum dose simvastatin and atorvastatin in patients with hypercholesterolemia: results of the Comparative HDL Efficacy and Safety Study (CHESS).

1 reference

12 December 2020

Differential effects of HDL subpopulations on cellular ABCA1- and SR-BI-mediated cholesterol efflux

1 reference

12 December 2020

Risk factors for a major coronary event after myocardial infarction in the Scandinavian Simvastatin Survival Study (4S). Impact of predicted risk on the benefit of cholesterol-lowering treatment

1 reference

12 December 2020

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

1 reference

12 December 2020

Comparison of effects of simvastatin versus atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I levels

1 reference

12 December 2020

Change in alpha1 HDL concentration predicts progression in coronary artery stenosis

1 reference

12 December 2020

Effects of switching statins on lipid and apolipoprotein ratios in the MERCURY I study

1 reference

12 December 2020

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines

1 reference

12 December 2020

Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial).

1 reference

12 December 2020

Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial

1 reference

12 December 2020

Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol <70 mg/dl and C-reactive protein <2 mg/l: an analysis of the PROVE-IT TIMI-22 trial

1 reference

12 December 2020

Comparing the effects of five different statins on the HDL subpopulation profiles of coronary heart disease patients

1 reference

12 December 2020

Effects of rosuvastatin, atorvastatin, simvastatin, and pravastatin on atherogenic dyslipidemia in patients with characteristics of the metabolic syndrome

1 reference

12 December 2020

Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia

1 reference

12 December 2020

Comparisons of effects of statins (atorvastatin, fluvastatin, lovastatin, pravastatin, and simvastatin) on fasting and postprandial lipoproteins in patients with coronary heart disease versus control subjects

1 reference

12 December 2020

Lipid-modifying effects of rosuvastatin in postmenopausal women with hypercholesterolemia who are receiving hormone replacement therapy

1 reference

12 December 2020

Comparison of rosuvastatin with atorvastatin, simvastatin and pravastatin in achieving cholesterol goals and improving plasma lipids in hypercholesterolaemic patients with or without the metabolic syndrome in the MERCURY I trial

1 reference

12 December 2020

Effects of cholesteryl ester transfer protein inhibition on high-density lipoprotein subspecies, apolipoprotein A-I metabolism, and fecal sterol excretion.

1 reference

12 December 2020

Effects of switching statins on achievement of lipid goals: Measuring Effective Reductions in Cholesterol Using Rosuvastatin Therapy (MERCURY I) study

1 reference

12 December 2020

Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS)

1 reference

12 December 2020

MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial

1 reference

12 December 2020

Efficacy and safety of rosuvastatin and atorvastatin in patients with hypercholesterolemia and a high risk of coronary heart disease: a randomized, controlled trial

1 reference

12 December 2020

Comparison of rosuvastatin versus atorvastatin in patients with heterozygous familial hypercholesterolemia

1 reference

12 December 2020

European guidelines on cardiovascular disease prevention in clinical practice: third joint task force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by

1 reference

12 December 2020

10.1007/S11883-006-0063-3

Identifiers

DOI

1 reference

13 August 2017

1 reference